The Technical AnalystExchange: EURONEXT Industry: Biotechnology
Abivax SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.31% €12.92
America/New_York / 17 mai 2024 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 812.89 mill |
| EPS: | -3.43 |
| P/E: | -3.77 |
| Earnings Date: | Apr 02, 2024 |
| SharesOutstanding: | 62.92 mill |
| Avg Daily Volume: | 0.0308 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | n/a | n/a | ||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.77 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -3.77 | industry: PE -7.48 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€1.500 (-88.39%) €-11.42 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
€ 12.40 - 13.44 ( +/- 4.02%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €12.92 (-0.31% ) |
| Volume | 0.0104 mill |
| Avg. Vol. | 0.0308 mill |
| % of Avg. Vol | 33.69 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ABVX.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ABVX.PA
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.